### 22. recalls that exposure at work is responsible for at least 120 000 deaths from cancer each year in the eu; looks forward to the forthcoming new eu strategic framework on health and safety at work for the 2021-2027 period , the regular update of directive 2004/37/ec of 29 april 2004 on the protection of workers from the risks related to exposure to carcinogens or mutagens at work23 , and the addition of further binding occupational exposure limits within that directive; welcomes the commission’s commitment to presenting a legislative proposal to further reduce workers’ exposure to asbestos in 2022; asks member states to facilitate recognition of and compensation for proven work-related cancers; stresses the need to ensure the best possible general and individual protection measures for healthcare workers handling anti-cancer drugs; ### 22. recalls that exposure at work is responsible for at least 120 000 deaths from cancer each year in the eu; welcomes the publication of the new eu strategic framework on health and safety at work for the period 2021-2027; regrets however the lack of ambition in this strategy to reduce incidence of work-related cancers in the eu; calls on the commission to increase this ambition as a matter of urgency , in that regard , emphasizes the importance of , the regular update of directive 2004/37/ec of 29 april 2004 on the protection of workers from the risks related to exposure to carcinogens or mutagens at work23 , and calls on the commission to accelerate the addition of further binding occupational exposure limits within that directive; with a goal of including the 50 most dangerous hazardous substances by 2024; welcomes the commission’s commitment to presenting a legislative proposal to further reduce workers’ exposure to asbestos in 2022; asks member states to facilitate recognition of and compensation for proven work-related cancers; and to reinforce the control of work-related exposure by labour inspectorates; stresses the need to ensure the best possible general and individual protection measures for healthcare workers handling hazardous medicinal products (hmp) by including these products in directive 2004/37/ec;


### 22. recalls that exposure at work is responsible for at least 120 000 deaths from cancer each year in the eu; looks forward to the forthcoming new eu strategic framework on health and safety at work for the 2021-2027 period , the regular update of directive 2004/37/ec of 29 april 2004 on the protection of workers from the risks related to exposure to carcinogens or mutagens at work23 , and the addition of further binding occupational exposure limits within that directive; welcomes the commission’s commitment to presenting a legislative proposal to further reduce workers’ exposure to asbestos in 2022; asks member states to facilitate recognition of and compensation for proven work-related cancers; stresses the need to ensure the best possible general and individual protection measures for healthcare workers handling anti-cancer drugs; ### 22. recalls that exposure at work is responsible for at least 120 000 deaths from cancer each year in the eu; looks forward to the forthcoming new eu strategic framework on health and safety at work for the 2021-2027 period , the regular update of directive 2004/37/ec of 29 april 2004 on the protection of workers from the risks related to exposure to carcinogens or mutagens at work23 , and the addition of further binding occupational exposure limits within that directive; welcomes the commission’s commitment to presenting a legislative proposal to further reduce workers’ exposure to asbestos in 2022; asks member states to facilitate recognition of and compensation for proven work-related cancers; stresses the need to ensure the best possible general and individual protection measures for healthcare workers handling anti-cancer drugs; points out that the automation and robotisation of certain activities can significantly reduce the risk of workers being exposed to carcinogens in workplaces;


### 23. encourages the commission and the member states to promote the prevention of cancers related to infectious diseases; recalls that human papillomavirus (hpv) is a sexually transmitted infection associated with uterine , cervical and oropharyngeal cancers; welcomes the vaccination programmes in the fight against hpv transmission; notes and regrets major discrepancies in vaccination coverage between member states , ranging from less than 30 % to more than 70 % (with the required level of population immunity being at 70 %); insists that a gender-neutral hpv vaccination programme be implemented in the member states to ensure the elimination of all hpv-related cancers; considers it important to draw up further recommendations to better implement these programmes; calls for more harmonisation of hpv and hepatitis b vaccination within member states’ national programmes , while ensuring the provision of information about and equal access to vaccination; supports further research into the most effective vaccination schedules against other carcinogenic viruses such as hepatitis c; calls for collaboration with member states and international organisations to combat the impact of misinformation on vaccination and address vaccine hesitancy; ### 23. encourages the commission and the member states to promote the prevention of cancers related to infectious diseases; recalls that human papillomavirus (hpv) is a sexually transmitted infection associated with uterine , cervical and oropharyngeal cancers; welcomes the vaccination programmes in the fight against hpv transmission; notes and regrets major discrepancies in vaccination coverage between member states , ranging from less than 30 % to more than 70 % (with the required level of population immunity being at 70 %); insists that a gender-neutral hpv vaccination programme be implemented in the member states to ensure the elimination of all hpv-related cancers; acknowledges that the covid-19 crisis has significantly disrupted hepatitis b immunization programmes for newborns , children and vulnerable and at-risk adult groups; calls on member states to implement the council recommendation of 7 december 2018 on strengthened cooperation against vaccine-preventable diseases (2018/c 466/01) to reduce immunization inequalities among vulnerable groups and improve childhood immunization; welcomes the commission’s intention to propose a council recommendation on vaccine-preventable cancers; calls for more harmonisation of hpv and hepatitis b vaccination within member states’ national programmes , while ensuring the provision of information about vaccination and promoting equal access for vulnerable and at-risk adult groups; supports further research into developing a vaccine for hepatitis c; calls for collaboration with member states and international organisations to combat the impact of misinformation on vaccination and address vaccine hesitancy;


### 23. encourages the commission and the member states to promote the prevention of cancers related to infectious diseases; recalls that human papillomavirus (hpv) is a sexually transmitted infection associated with uterine , cervical and oropharyngeal cancers; welcomes the vaccination programmes in the fight against hpv transmission; notes and regrets major discrepancies in vaccination coverage between member states , ranging from less than 30 % to more than 70 % (with the required level of population immunity being at 70 %); insists that a gender-neutral hpv vaccination programme be implemented in the member states to ensure the elimination of all hpv-related cancers; considers it important to draw up further recommendations to better implement these programmes; calls for more harmonisation of hpv and hepatitis b vaccination within member states’ national programmes , while ensuring the provision of information about and equal access to vaccination; supports further research into the most effective vaccination schedules against other carcinogenic viruses such as hepatitis c; calls for collaboration with member states and international organisations to combat the impact of misinformation on vaccination and address vaccine hesitancy; ### 23. encourages the commission and the member states to promote the prevention of cancers related to infectious diseases; recalls that human papillomavirus (hpv) is a sexually transmitted infection associated with uterine , cervical , vaginal , vulvar , penile , anal and oropharyngeal cancers; welcomes the vaccination programmes in the fight against hpv transmission; notes and regrets major discrepancies in vaccination coverage between member states , ranging from less than 30 % to more than 70 % (with the required level of population immunity being at 70 %); calls for 90% of girls to be fully vaccinated with the hpv vaccine by the age of 15 by 2030 , insists that a gender-neutral hpv vaccination programme be implemented in the member states to ensure the elimination of all hpv-related cancers; calls on the member states to ensure that their national hpv programmes increase coverage rates by vaccinating the adult population , as well as risk groups (i.e. older women , men having sex with men , persons with immunocompromising conditions) , considers it important to draw up further recommendations to better implement these programmes; calls for more harmonisation of hpv and hepatitis b vaccination within member states’ national programmes , while ensuring the provision of information about and equal access to vaccination; encourages the regular monitoring of current hpv and hepatitis b vaccination at eu level , supports further research into the most effective vaccination schedules against other carcinogenic viruses such as hepatitis c; calls for collaboration with member states and international organisations to combat the impact of misinformation on vaccination and address vaccine hesitancy;


### 23. encourages the commission and the member states to promote the prevention of cancers related to infectious diseases; recalls that human papillomavirus (hpv) is a sexually transmitted infection associated with uterine , cervical and oropharyngeal cancers; welcomes the vaccination programmes in the fight against hpv transmission; notes and regrets major discrepancies in vaccination coverage between member states , ranging from less than 30 % to more than 70 % (with the required level of population immunity being at 70 %); insists that a gender-neutral hpv vaccination programme be implemented in the member states to ensure the elimination of all hpv-related cancers; considers it important to draw up further recommendations to better implement these programmes; calls for more harmonisation of hpv and hepatitis b vaccination within member states’ national programmes , while ensuring the provision of information about and equal access to vaccination; supports further research into the most effective vaccination schedules against other carcinogenic viruses such as hepatitis c; calls for collaboration with member states and international organisations to combat the impact of misinformation on vaccination and address vaccine hesitancy; ### 23. encourages the commission and the member states to promote the prevention of cancers related to infectious diseases; recalls that human papillomavirus (hpv) is a sexually transmitted infection associated with uterine , cervical , vaginal , vulvar , penile , anal and oropharyngeal cancers; welcomes the vaccination programmes in the fight against hpv transmission; notes and regrets major discrepancies in vaccination coverage between member states , ranging from less than 30 % to more than 70 % (with the required level of population immunity being at 70 %); insists that a gender-neutral hpv vaccination programme be implemented in the member states to ensure the elimination of all hpv-related cancers; calls on the member states to ensure that their national hpv programmes increase coverage rates by vaccinating the adult population , as well as identified high risk groups; considers it important to draw up further recommendations to better implement these programmes; calls for more harmonisation of hpv and hepatitis b vaccination within member states’ national programmes , while ensuring the provision of information about and equal access to vaccination; encourages the regular monitoring of current hpv and hepatitis b vaccination at european level; supports further research into the most effective vaccination schedules against other carcinogenic viruses such as hepatitis c; calls for collaboration with member states and international organisations to combat the impact of misinformation on vaccination and address vaccine hesitancy;


### 23. encourages the commission and the member states to promote the prevention of cancers related to infectious diseases; recalls that human papillomavirus (hpv) is a sexually transmitted infection associated with uterine , cervical and oropharyngeal cancers; welcomes the vaccination programmes in the fight against hpv transmission; notes and regrets major discrepancies in vaccination coverage between member states , ranging from less than 30 % to more than 70 % (with the required level of population immunity being at 70 %); insists that a gender-neutral hpv vaccination programme be implemented in the member states to ensure the elimination of all hpv-related cancers; considers it important to draw up further recommendations to better implement these programmes; calls for more harmonisation of hpv and hepatitis b vaccination within member states’ national programmes , while ensuring the provision of information about and equal access to vaccination; supports further research into the most effective vaccination schedules against other carcinogenic viruses such as hepatitis c; calls for collaboration with member states and international organisations to combat the impact of misinformation on vaccination and address vaccine hesitancy; ### 23. encourages the commission and the member states to promote the prevention of cancers related to infectious diseases; recalls that human papillomavirus (hpv) is a sexually transmitted infection associated with uterine , cervical and oropharyngeal cancers; welcomes the vaccination programmes in the fight against hpv transmission; notes and regrets major discrepancies in vaccination coverage between member states , ranging from less than 30 % to more than 70 % (with the required level of population immunity being at 70 %); insists that a gender-neutral hpv vaccination programme be implemented in the member states , subject to localised context-specific evaluations , to ensure the elimination of all hpv-related cancers; calls for improving the uptake of hpv vaccination in line with the who global strategy on the elimination of cervical cancer encompassing vaccination as well as screening , access to treatment , and rehabilitation; considers it important to draw up further recommendations to better implement these programmes; calls for more harmonisation of hpv and hepatitis b vaccination within member states’ national programmes , while ensuring the provision of information about and equal access to vaccination; supports further research into the most effective vaccination schedules against other carcinogenic viruses such as hepatitis c; calls for collaboration with member states and international organisations to combat the impact of misinformation on vaccination and address vaccine hesitancy;


### 23. encourages the commission and the member states to promote the prevention of cancers related to infectious diseases; recalls that human papillomavirus (hpv) is a sexually transmitted infection associated with uterine , cervical and oropharyngeal cancers; welcomes the vaccination programmes in the fight against hpv transmission; notes and regrets major discrepancies in vaccination coverage between member states , ranging from less than 30 % to more than 70 % (with the required level of population immunity being at 70 %); insists that a gender-neutral hpv vaccination programme be implemented in the member states to ensure the elimination of all hpv-related cancers; considers it important to draw up further recommendations to better implement these programmes; calls for more harmonisation of hpv and hepatitis b vaccination within member states’ national programmes , while ensuring the provision of information about and equal access to vaccination; supports further research into the most effective vaccination schedules against other carcinogenic viruses such as hepatitis c; calls for collaboration with member states and international organisations to combat the impact of misinformation on vaccination and address vaccine hesitancy; ### 23. encourages the commission and the member states to promote the prevention of cancers related to infectious diseases; recalls that human papillomavirus (hpv) is a sexually transmitted infection associated with uterine , cervical and oropharyngeal cancers; welcomes the vaccination programmes in the fight against hpv transmission; notes and regrets major discrepancies in vaccination coverage between member states , ranging from less than 30 % to more than 70 % (with the required level of population immunity being at 90 % of girls by the age of 15 by 2030); insists that a gender-neutral hpv vaccination programme be implemented in the member states to ensure the elimination of all hpv-related cancers; highlights the importance of tackling vaccine hesitancy across the european region; considers it important to draw up further recommendations to better implement these programmes; calls for more harmonisation of hpv and hepatitis b vaccination within member states’ national programmes , while ensuring the provision of information about and equal access to vaccination; supports further research into the most effective vaccination schedules against other carcinogenic viruses such as hepatitis c; calls for collaboration with member states and international organisations to combat the impact of misinformation on vaccination and address vaccine hesitancy;


### 23. encourages the commission and the member states to promote the prevention of cancers related to infectious diseases; recalls that human papillomavirus (hpv) is a sexually transmitted infection associated with uterine , cervical and oropharyngeal cancers; welcomes the vaccination programmes in the fight against hpv transmission; notes and regrets major discrepancies in vaccination coverage between member states , ranging from less than 30 % to more than 70 % (with the required level of population immunity being at 70 %); insists that a gender-neutral hpv vaccination programme be implemented in the member states to ensure the elimination of all hpv-related cancers; considers it important to draw up further recommendations to better implement these programmes; calls for more harmonisation of hpv and hepatitis b vaccination within member states’ national programmes , while ensuring the provision of information about and equal access to vaccination; supports further research into the most effective vaccination schedules against other carcinogenic viruses such as hepatitis c; calls for collaboration with member states and international organisations to combat the impact of misinformation on vaccination and address vaccine hesitancy; ### 23. encourages the commission and the member states to promote the prevention of cancers related to infectious diseases; recalls that human papillomavirus (hpv) is a sexually transmitted infection associated with uterine , cervical and mouth and throat cancers; welcomes the vaccination programmes in the fight against hpv transmission; notes and regrets major discrepancies in vaccination coverage between member states , ranging from less than 30 % to more than 70 % (with the required level of population immunity being at 70 %); insists that a gender-neutral hpv vaccination programme be implemented in the member states to ensure the elimination of all hpv-related cancers; considers it important to draw up further recommendations to better implement these programmes; calls for more harmonisation of hpv and hepatitis b vaccination within member states’ national programmes , while ensuring the provision of easy-to-understand and user-friendly information about and equal access to vaccination; supports further research into the most effective vaccination schedules against other carcinogenic viruses such as hepatitis c; calls for collaboration with member states and international organisations to combat the impact of misinformation on vaccination and address vaccine hesitancy;


### 25. points out that genetic predisposition to cancer linked to mutations of specific genes has been demonstrated; highlights that methods to detect these mutations are available , especially for breast and colorectal cancers , and may help to prevent or detect early-stage cancer; recommends investments in infrastructures and skills in genetic sequencing platforms and the training of specialised genetic counsellors; ### 25. points out that genetic predisposition to cancer linked to mutations of specific genes has been demonstrated; highlights that methods to detect these mutations are available , especially for breast and colorectal cancers , and may help to prevent or detect early-stage cancer; recommends investments in infrastructures and skills in genetic sequencing platforms and the training of specialised genetic counsellors; calls on the member states to earmark separate financing and ensure that citizens of all age groups can have their dna tested for genes that increase the risk of cancer , based on the most current medical knowledge , and to ensure that adequate mitigation measures can be undertaken , corresponding to the risk detected and in all age groups;


### 25. points out that genetic predisposition to cancer linked to mutations of specific genes has been demonstrated; highlights that methods to detect these mutations are available , especially for breast and colorectal cancers , and may help to prevent or detect early-stage cancer; recommends investments in infrastructures and skills in genetic sequencing platforms and the training of specialised genetic counsellors; ### 25. points out that genetic predisposition to cancer linked to mutations of specific genes has been demonstrated; highlights that methods to detect these mutations are available , especially for breast and colorectal cancers , and may help to prevent or detect early-stage cancer; recommends investments in infrastructures and skills in genetic sequencing platforms and the training of specialised genetic counsellors; calls for the recognition of the essential role of high quality surgery in the reduction of cancer risk in patients with hereditary susceptibility;


### 25. points out that genetic predisposition to cancer linked to mutations of specific genes has been demonstrated; highlights that methods to detect these mutations are available , especially for breast and colorectal cancers , and may help to prevent or detect early-stage cancer; recommends investments in infrastructures and skills in genetic sequencing platforms and the training of specialised genetic counsellors; ### 25. points out that genetic predisposition to cancer linked to mutations of specific genes has been demonstrated; highlights that methods to detect these mutations are available , especially for breast and colorectal cancers , and may help to prevent or detect early-stage cancer; recommends investments in infrastructures and skills in genetic sequencing platforms and the training of specialised genetic counsellors; urges to raise awareness about citizens' access to such services across europe via exercises such as the cancer inequalities registry;


### 25. points out that genetic predisposition to cancer linked to mutations of specific genes has been demonstrated; highlights that methods to detect these mutations are available , especially for breast and colorectal cancers , and may help to prevent or detect early-stage cancer; recommends investments in infrastructures and skills in genetic sequencing platforms and the training of specialised genetic counsellors; ### 25. points out that genetic predisposition to cancer linked to mutations of specific genes has been demonstrated; highlights that methods to detect these mutations are available , especially for breast and colorectal cancers , and may help to prevent or detect early-stage cancer; recommends investments in infrastructures and skills in genetic sequencing platforms and the training of specialised genetic counsellors; recommends work on making these solutions more widely available to eu citizens;


### 25. points out that genetic predisposition to cancer linked to mutations of specific genes has been demonstrated; highlights that methods to detect these mutations are available , especially for breast and colorectal cancers , and may help to prevent or detect early-stage cancer; recommends investments in infrastructures and skills in genetic sequencing platforms and the training of specialised genetic counsellors; ### 25. points out that genetic predisposition to cancer linked to mutations of specific genes has been demonstrated; highlights that methods to detect these mutations are available , especially for breast , ovarian and colorectal cancers , and may help to prevent or detect early-stage cancer and provide guidelines for available treatment options; recommends investments in infrastructures and skills in genetic sequencing platforms and the training of specialised genetic counsellors;


### 25. points out that genetic predisposition to cancer linked to mutations of specific genes has been demonstrated; highlights that methods to detect these mutations are available , especially for breast and colorectal cancers , and may help to prevent or detect early-stage cancer; recommends investments in infrastructures and skills in genetic sequencing platforms and the training of specialised genetic counsellors; ### 25. points out that genetic predisposition to cancer linked to mutations of specific genes has been demonstrated; highlights that methods to detect these mutations are available , especially for breast , colorectal and ovarian cancers , and may help to prevent or detect early-stage cancer , and guide treatment choice; recommends investments in infrastructures and skills in genetic sequencing platforms and the training of specialised genetic counsellors;


### 25. points out that genetic predisposition to cancer linked to mutations of specific genes has been demonstrated; highlights that methods to detect these mutations are available , especially for breast and colorectal cancers , and may help to prevent or detect early-stage cancer; recommends investments in infrastructures and skills in genetic sequencing platforms and the training of specialised genetic counsellors; ### 25. points out that genetic predisposition to cancer linked to mutations of specific genes has been demonstrated; highlights that methods to detect these mutations are available , especially for breast and colorectal cancers as well as some childhood cancers , and may help to prevent or detect early-stage cancer; recommends investments in infrastructures and skills in genetic sequencing platforms and the training of specialised genetic counsellors;


### 26. strongly supports the planned revision of the ecac and the launch of an eu mobile app for cancer prevention and care , as announced in europe’s beating cancer plan , in order to develop , share and implement best practices in cancer prevention and care programmes , with a focus on disadvantaged groups; stresses that the ecac should be systematically evaluated and that the evaluation work should be coordinated by the iarc; ### 26. strongly supports the planned revision of the ecac and the launch of an eu mobile app for cancer prevention and care , as announced in europe’s beating cancer plan , in order to develop , share and implement best practices in cancer prevention and care programmes , with a focus on disadvantaged groups; proposes that programmes be set up to support and encourage prevention aimed specifically at disadvantaged groups in order to reach as many people as possible; stresses that the ecac should be systematically evaluated and that the evaluation work should be coordinated by the iarc;


### 26. strongly supports the planned revision of the ecac and the launch of an eu mobile app for cancer prevention and care , as announced in europe’s beating cancer plan , in order to develop , share and implement best practices in cancer prevention and care programmes , with a focus on disadvantaged groups; stresses that the ecac should be systematically evaluated and that the evaluation work should be coordinated by the iarc; ### 26. strongly supports the planned revision of the ecac and the launch of an eu mobile platform accompanying patients from cancer prevention and education to care , as announced in europe’s beating cancer plan , in order to develop , share and implement best practices in cancer prevention and care programmes , with a focus on disadvantaged groups; stresses that the ecac should be systematically evaluated and that the evaluation work should be coordinated by the iarc;


### 28. calls for the creation of a virtual european cancer institute , which would be in charge of establishing a european roadmap to devise and coordinate large-scale prevention campaigns and effective communication campaigns on health promotion in educational programmes (harmless behaviours , healthy nutrition , physical activity etc.) with a special focus on young people and disadvantaged groups; ### 28. calls for the creation of a virtual european cancer institute , which would be in charge of establishing a european roadmap to devise and coordinate large-scale prevention campaigns and effective communication campaigns on health promotion in educational programmes (behaviours , healthy nutrition , physical activity , transmission routes of carcinogenic viruses and vaccination and treatment opportunities for such infections , information about the need to get tested when exposed to risk) with a special focus on young people and disadvantaged groups;


### 29. underlines that tobacco and alcohol consumption , poor nutrition , a high body mass index and a sedentary lifestyle are risk factors common to other chronic diseases; believes , therefore , that cancer prevention has to be implemented in the context of an integrated chronic disease prevention programme , in close cooperation with the steering group on health promotion , disease prevention and management of non-communicable diseases; ### 29. underlines that tobacco and alcohol consumption , poor nutrition , a high body mass index , and a sedentary lifestyle are risk factors common to other chronic diseases , and illicit drug use and unsafe sex contributes to the spread of carcinogenic viruses and development of chronic diseases; believes , therefore , that cancer prevention has to be implemented in the context of an integrated chronic disease prevention programme , in close cooperation with the steering group on health promotion , disease prevention and management of non-communicable diseases; deplores that cancer prevention is largely seen in the context of non-communicable diseases; thus encourages the commission to extend the mandate of the eu steering group on health promotion , disease prevention and management of non-communicable diseases to help member states reach the un sdgs targeting communicable diseases , in order to better tackle carcinogenic viruses;


### 29. underlines that tobacco and alcohol consumption , poor nutrition , a high body mass index and a sedentary lifestyle are risk factors common to other chronic diseases; believes , therefore , that cancer prevention has to be implemented in the context of an integrated chronic disease prevention programme , in close cooperation with the steering group on health promotion , disease prevention and management of non-communicable diseases; ### 29. underlines that tobacco and harmful alcohol consumption , poor nutrition , a high body mass index and a sedentary lifestyle are risk factors common to other chronic diseases; believes , therefore , that cancer prevention has to be implemented in the context of an integrated chronic disease prevention programme , by establishing knowledge-based and risk-proportionate regulatory standards , in close cooperation with the steering group on health promotion , disease prevention and management of non-communicable diseases;


### 29. underlines that tobacco and alcohol consumption , poor nutrition , a high body mass index and a sedentary lifestyle are risk factors common to other chronic diseases; believes , therefore , that cancer prevention has to be implemented in the context of an integrated chronic disease prevention programme , in close cooperation with the steering group on health promotion , disease prevention and management of non-communicable diseases; ### 29. underlines that tobacco and harmful alcohol consumption , poor nutrition , a high body mass index and a sedentary lifestyle are risk factors common to other chronic diseases; believes , therefore , that cancer prevention has to be implemented in the context of an integrated chronic disease prevention programme , in close cooperation with the steering group on health promotion , disease prevention and management of non-communicable diseases;


### 29. underlines that tobacco and alcohol consumption , poor nutrition , a high body mass index and a sedentary lifestyle are risk factors common to other chronic diseases; believes , therefore , that cancer prevention has to be implemented in the context of an integrated chronic disease prevention programme , in close cooperation with the steering group on health promotion , disease prevention and management of non-communicable diseases; ### 29. underlines that tobacco , harmful alcohol consumption , poor nutrition , a high body mass index and a sedentary lifestyle are risk factors common to other chronic diseases; believes , therefore , that cancer prevention has to be implemented in the context of an integrated chronic disease prevention programme , in close cooperation with the steering group on health promotion , disease prevention and management of non-communicable diseases;


### 30. calls for the implementation of prevention programmes to be inclusive , by involving citizens , civil society and patient associations , especially through the conference on the future of europe; ### 30. calls for the implementation of prevention programmes to be inclusive , by involving citizens , civil society and patient associations , at all steps of decision-making process , ensuring substantial funding and support to these organisations; especially through the conference on the future of europe;


### 30. calls for the implementation of prevention programmes to be inclusive , by involving citizens , civil society and patient associations , especially through the conference on the future of europe; ### 30. calls for the implementation of prevention programmes to be inclusive , by involving municipalities and regions , citizens , civil society and patient associations , especially through the conference on the future of europe;


### 31. deplores the frequent delays to cancer diagnosis related to a lack of information or adherence to cancer screening and detection processes; recognises the need to pay particular attention to the continuity of screening programmes and early detection in the context of a health crisis (such as the covid-19 crisis); ### 31. deplores the frequent delays to cancer diagnosis related to a lack of information or adherence to cancer screening and detection processes; recognises the need to pay particular attention to the continuity of screening programmes , early detection and cancer care service in the context of a health crisis (such as the covid-19 crisis); stresses the importance of quick and up-to-date data on cancer screening programmes to enable swift reaction and follow-up in case of disruptions in regular screening capabilities with a goal of reducing the number of postponed screenings to an absolute minimum;


### 31. deplores the frequent delays to cancer diagnosis related to a lack of information or adherence to cancer screening and detection processes; recognises the need to pay particular attention to the continuity of screening programmes and early detection in the context of a health crisis (such as the covid-19 crisis); ### 31. deplores the frequent delays to cancer diagnosis related to a lack of information or adherence to cancer screening and detection processes; recognises the need to pay particular attention to the continuity of screening programmes , early detection and cancer care services in the context of a health crisis (such as the covid-19 crisis); encourages the commission and member states to organise , in partnership with cancer stakeholders , public health campaigns to address any delays in screening , early detection and care that a health crisis might cause;


### 31. deplores the frequent delays to cancer diagnosis related to a lack of information or adherence to cancer screening and detection processes; recognises the need to pay particular attention to the continuity of screening programmes and early detection in the context of a health crisis (such as the covid-19 crisis); ### 31. deplores the frequent delays to cancer diagnosis related to a lack of information or adherence to cancer screening and detection processes; recognises the need to pay particular attention to the continuity of screening programmes and early detection and cancer care services in the context of a health crisis (such as the covid-19 crisis); urges the commission and member states to address and mitigate potential delays in cancer screening , early detection and care caused by a health crisis , through public health campaigns with the participation of all relevant stakeholders;


### 31. deplores the frequent delays to cancer diagnosis related to a lack of information or adherence to cancer screening and detection processes; recognises the need to pay particular attention to the continuity of screening programmes and early detection in the context of a health crisis (such as the covid-19 crisis); ### 31. deplores the frequent delays to cancer diagnosis related to a lack of information or adherence to cancer screening and detection processes; recognises the need to pay particular attention to the continuity of screening programmes and early detection in the context of a health crisis (such as the covid-19 crisis); stresses the importance of quick and up-to-date data on cancer screening programmes to enable swift reaction and follow-up in case of disruptions in regular screening capabilities with a goal of reducing the number of postponed screenings to an absolute minimum;


### 32. notes that , for instance , only 18 member states reported that they had national or regional population-based screening programmes in place; regrets the inequalities between member states in access to breast cancer screening , which differs at least tenfold across the eu according to eurostat; ### 32. notes that , for instance , only 18 member states reported that they had national or regional population-based screening programmes in place; regrets the inequalities between member states in access , notably to breast cancer screening , which differs at least tenfold across the eu according to eurostat;


### 33. invites member states to work together to reduce inequalities in cancer screening and early diagnosis services , especially in cross-border regions; ### 33. invites member states to work together to reduce social and geographical inequalities in cancer screening and early diagnosis services , especially in cross-border regions , including by sharing best practices in a more coordinated way , such as through a european platform for national screening agencies;


### 33. invites member states to work together to reduce inequalities in cancer screening and early diagnosis services , especially in cross-border regions; ### 33. invites member states to work together to reduce inequalities in cancer screening and early diagnosis services , especially in cross-border regions; encourages the commission to support and fund activities to promote and raise awareness of screening;


### 33. invites member states to work together to reduce inequalities in cancer screening and early diagnosis services , especially in cross-border regions; ### 33. invites member states to work together to reduce social and geographical inequalities in cancer screening and early diagnosis services , especially in cross-border regions;


### 34. supports the launch of a new eu-supported cancer screening scheme , as announced in europe’s beating cancer plan , to help member states to ensure that 90 % of the eu population who qualify for breast , cervical and colorectal cancer screenings are offered screening by 2025; ### 34. supports the launch of a new eu-supported cancer screening scheme , as announced in europe’s beating cancer plan , to help member states to ensure that 90 % of the eu population who qualify for breast , cervical and colorectal cancer screenings are offered screening by 2025; and calls for the establishment of a permanent platform to enable the networking of cancer screening programme coordinators , facilitate the training and capacity-building for improving quality in screening programmes , act as central hub for projects and initiatives on cancer screening supported by the eu , and maintain in the long term the network of data providers to the implementation report by the iarc on cancer screening in the european union;


### 34. supports the launch of a new eu-supported cancer screening scheme , as announced in europe’s beating cancer plan , to help member states to ensure that 90 % of the eu population who qualify for breast , cervical and colorectal cancer screenings are offered screening by 2025; ### 34. supports the launch of a new eu-supported cancer screening scheme , as announced in europe’s beating cancer plan , to help member states to ensure that 90 % of the eu population who qualify for breast , cervical and colorectal cancer screenings are offered screening by 2025; supports research on other types of cancers , which may be effectively detected by screening;


### 34. supports the launch of a new eu-supported cancer screening scheme , as announced in europe’s beating cancer plan , to help member states to ensure that 90 % of the eu population who qualify for breast , cervical and colorectal cancer screenings are offered screening by 2025; ### 34. supports the launch of a new eu-supported cancer screening scheme , as announced in europe’s beating cancer plan , to help member states to ensure that 90 % of the eu population who qualify for breast , cervical and colorectal cancer screenings are offered screening by 2025; supports research into other cancers that can be effectively detected by screening;


### 34. supports the launch of a new eu-supported cancer screening scheme , as announced in europe’s beating cancer plan , to help member states to ensure that 90 % of the eu population who qualify for breast , cervical and colorectal cancer screenings are offered screening by 2025; ### 34. supports the launch of a new eu-supported cancer screening scheme , as announced in europe’s beating cancer plan , to help member states to ensure that 90 % of the eu population who qualify for breast , cervical , lung , and colorectal cancer screenings are offered screening by 2025;


### 35. encourages member states to promote cancer screening for breast , cervical and colorectal cancers as part of organised population-based national and regional programmes , including in the remote and outermost regions , and provide adequate resources; recommends that member states roll out programmes for early clinical detection of oral and skin cancers; ### 35. encourages member states to promote cancer screening for breast , cervical and colorectal cancers as part of organised population-based national and regional programmes , including in the remote and outermost regions , and provide adequate resources; encourages the commission and the member states to promote targeted screening for high-risk groups such as hereditary breast cancer , based on the available evidence; recommends that member states roll out programmes for early clinical detection of oral and skin cancers;


### 36. calls for the full implementation by member states of the european guidelines for quality assurance in cancer screening for breast , cervical and colorectal cancers and early detection services , to minimise the delay to diagnosis for such cancers; recommends that inequalities within member states regarding screening be addressed , possibly by making the criteria for cancer screening , as well as the legal frameworks , governance and quality assurance structures , more stringent; ### 36. calls for the full implementation by member states of the european guidelines for quality assurance in cancer screening for breast , lung , stomach , cervical and colorectal cancers and early detection services , to minimise the delay to diagnosis for such cancers; recommends that inequalities within member states regarding screening be addressed , possibly by making the criteria for cancer screening , as well as the legal frameworks , governance and quality assurance structures , more stringent; encourages proposing measures to involve employers in promotional activities to encourage the use of screening;


### 37. encourages the improvement and harmonisation of cancer screening data collection to allow for an annual european report; encourages , too , the regular monitoring of current screening programmes at eu level; underlines that scientific advances in cancer risk prediction should allow for the development of risk-appropriate screening programmes; ### 37. encourages the improvement and harmonisation of cancer screening data collection to allow for an annual european report; encourages , too , the regular monitoring of current screening programmes at eu level; highlights the need to link data sets from screening programmes on cancer incidence with occupational categories , which can help to identify appropriate preventive measures; underlines that scientific advances in cancer risk prediction should allow for the development of risk-appropriate screening programmes;


### 38. welcomes the upcoming update of the 2003 council recommendation on breast , cervical and colorectal cancer screening24 to take into account new screening tests and the most recent data on the best screening protocols (magnetic resonance imaging , hpv testing); emphasises that those programmes should be regularly evaluated by the competent national authorities; calls for research efforts to be fostered in order to assess , in close cooperation with the iarc and the who , the possible inclusion of new science-based cancer screening programmes (including lung , prostate , stomach and ovarian cancers) in the recommendation; ### 38. welcomes the process initiated by the commission’s group of chief scientific advisors and the scientific advice mechanism on the upcoming update of the 2003 council recommendation on breast , cervical and colorectal cancer screening24 to take into account new screening tests programmes including lung , prostate and gastric cancers on the basis of the and the most recent data on the best screening protocols (magnetic resonance imaging , hpv testing); calls for lung cancer screening guidelines in line with the most recent scientific evidence emphasises that those programmes should be regularly evaluated by the competent national authorities; calls for to recognize the extensive body of evidence that proves the positive effect of targeted lung cancer screening; encourages the council to include lung and prostate cancer screening in the update of the council recommendations in 2022; calls on the council to mandate the commission to develop eu guidelines research efforts to be fostered in order to assess , in close cooperation with the iarc and the who , the possible inclusion of new science-based cancer screening programmes and the role of ai (including lung , prostate , stomach and ovarian cancers) in the recommendation.


### 38. welcomes the upcoming update of the 2003 council recommendation on breast , cervical and colorectal cancer screening24 to take into account new screening tests and the most recent data on the best screening protocols (magnetic resonance imaging , hpv testing); emphasises that those programmes should be regularly evaluated by the competent national authorities; calls for research efforts to be fostered in order to assess , in close cooperation with the iarc and the who , the possible inclusion of new science-based cancer screening programmes (including lung , prostate , stomach and ovarian cancers) in the recommendation; ### 38. welcomes the process initiated by the commission’s group of chief scientific advisors and the scientific advice mechanism on the upcoming update of the 2003 council recommendation on breast , cervical and colorectal cancer screening24 to take into account new screening programmes including lung , prostate and gastric cancers on the basis of the most recent data on the best screening protocols (magnetic resonance imaging , hpv testing , low dose computer tomography , risk stratified approaches and risk calculators); emphasises that those programmes should be regularly evaluated by the competent national authorities and the jrc cancer knowledge centre; calls for close cooperation with the iarc , the who , healthcare professionals and patient groups;


### 38. welcomes the upcoming update of the 2003 council recommendation on breast , cervical and colorectal cancer screening24 to take into account new screening tests and the most recent data on the best screening protocols (magnetic resonance imaging , hpv testing); emphasises that those programmes should be regularly evaluated by the competent national authorities; calls for research efforts to be fostered in order to assess , in close cooperation with the iarc and the who , the possible inclusion of new science-based cancer screening programmes (including lung , prostate , stomach and ovarian cancers) in the recommendation; ### 38. welcomes the upcoming update of the 2003 council recommendation on breast , cervical and colorectal cancer screening24 to take into account new screening tests and the most recent data on the best screening protocols (magnetic resonance imaging , hpv testing); emphasises that those programmes should be regularly evaluated by the competent national authorities; calls for research efforts to be fostered in order to assess , in close cooperation with the iarc and the who , the possible inclusion of new science-based cancer screening programmes and the role of ai (including lung , prostate , stomach and ovarian cancers) in the recommendation;


### 38. welcomes the upcoming update of the 2003 council recommendation on breast , cervical and colorectal cancer screening24 to take into account new screening tests and the most recent data on the best screening protocols (magnetic resonance imaging , hpv testing); emphasises that those programmes should be regularly evaluated by the competent national authorities; calls for research efforts to be fostered in order to assess , in close cooperation with the iarc and the who , the possible inclusion of new science-based cancer screening programmes (including lung , prostate , stomach and ovarian cancers) in the recommendation; ### 38. welcomes the upcoming update of the 2003 council recommendation on breast , cervical and colorectal cancer screening24 to take into account new screening tests and the most recent data on the best screening protocols (magnetic resonance imaging , hpv testing); emphasises that those programmes should be regularly evaluated by the competent national authorities; calls for research efforts to be fostered in order to assess , in close cooperation with the iarc and the who , the possible inclusion of new science-based cancer screening programmes (including lung , prostate , stomach , ovarian and skin cancers) in the recommendation;


### 39. advocates the launch of a platform for national screening centres to share expertise and implement best practices , discuss common challenges and encourage collaboration , based on the model of the european network for health technology assessment (eunethta); ### 39. advocates the launch of a platform for national screening centres to share expertise and implement best practices , discuss common challenges and encourage collaboration , based on the model of the european network for health technology assessment (eunethta) and the heads of medicines agencies (hma);


### 40. stresses the importance of increasing the uptake of cancer screening and early detection among eu citizens through european awareness days , motivation surveys and better implementation of existing communication campaigns; ### 40. stresses the importance of increasing awareness about , and the uptake of , cancer screening and early detection among eu citizens through european awareness days , motivation surveys and better implementation of existing communication campaigns; encourages research into behavioural adherence factors to boost participation in screening programmes , supported by the horizon europe research programme;


### 40. stresses the importance of increasing the uptake of cancer screening and early detection among eu citizens through european awareness days , motivation surveys and better implementation of existing communication campaigns; ### 40. stresses the importance of increasing the uptake of cancer screening and early detection among eu citizens through a union-wide communication and awareness campaign , european awareness days , motivation surveys and better implementation of existing communication campaigns; notes that such campaigns are particularly important for lung cancer , the leading cause of cancer death;


### 40. stresses the importance of increasing the uptake of cancer screening and early detection among eu citizens through european awareness days , motivation surveys and better implementation of existing communication campaigns; ### 40. stresses the importance of increasing the uptake of cancer screening and early detection among eu citizens through european awareness days , motivation surveys and better implementation of existing communication campaigns; calls on member states to implement awareness-raising actions in order to improve participation in screening;


### 41. calls for reinforced cooperation with third countries to encourage the organisation of screening campaigns , in particular for women’s cancers and notably in low- and middle-income countries; ### 41. calls for reinforced cooperation with third countries to encourage the organisation of screening campaigns , in particular for women’s cancers and notably in low- and middle-income countries; this can mark an important contribution by the eu towards the achievement of international goals in cancer , such as the who goal for the elimination of cervical cancer as a public health problem;


### 41. calls for reinforced cooperation with third countries to encourage the organisation of screening campaigns , in particular for women’s cancers and notably in low- and middle-income countries; ### 41. calls for reinforced cooperation with third countries and in particular with the broader european region , to encourage the organisation of early diagnosis programmes , in particular for women’s cancers and notably in low- and middle-income countries;


### 41. calls for reinforced cooperation with third countries to encourage the organisation of screening campaigns , in particular for women’s cancers and notably in low- and middle-income countries; ### 41. calls for reinforced cooperation with third countries to encourage the organisation of screening campaigns , in particular for women’s cancers and notably in low- and middle-income countries; and with minority communities;


### 42. deplores the fact that eu patients still face challenges in accessing healthcare services in other member states and that only a minority of patients are aware of their right to seek cross-border healthcare; emphasises the need for better implementation of , and an improved financial model for , the cross-border healthcare directive25 to allow for mobility and access to highly specialised equipment and care through the reinforcement of the national contact points (ncps) by providing them with more budgetary resources , and calls for an increase in the number of information campaigns on patients’ rights to cross-border healthcare; emphasises the need to facilitate the process , through the revision of the cross-border healthcare directive , for patients who travel abroad for clinical trials and face issues such as a lack of clarity on follow-up protocols after their return home and on coverage of costs related to their clinical trial participation by national insurance agencies; calls on the commission and the member states to work together to conduct regular evaluations of the commission’s ehealth strategy from 2018 to ensure interconnected electronic health records for cancer patients at regional , national and european level; ### 42. deplores the fact that eu patients still face challenges in accessing healthcare services in other member states and that only a minority of patients are aware of their right to seek cross-border healthcare; calls for a radical reform of the cross-border healthcare directive25 to allow for mobility and access to highly specialised equipment and care through the reinforcement of the national contact points (ncps) by providing them with more budgetary resources , and calls for an increase in the number of information campaigns on patients’ rights to cross-border healthcare , including those aimed to health professionals; emphasises the need to facilitate the process , through the revision of the cross-border healthcare directive , for patients who travel abroad for clinical trials and face issues such as a lack of clarity on follow-up protocols after their return home and on coverage of costs related to their clinical trial participation by national insurance agencies; calls on the commission to merge the authorisation and reimbursement rules of regulation 883/2004 on the coordination of social security systems with the cross- border healthcare directive to provide clarity and transparency for patients and healthcare professionals , including a right for second opinion; calls on the commission and the member states to work together to conduct regular evaluations of the commission’s ehealth strategy from 2018 to ensure interconnected electronic health records for cancer patients at regional , national and european level;


### 42. deplores the fact that eu patients still face challenges in accessing healthcare services in other member states and that only a minority of patients are aware of their right to seek cross-border healthcare; emphasises the need for better implementation of , and an improved financial model for , the cross-border healthcare directive25 to allow for mobility and access to highly specialised equipment and care through the reinforcement of the national contact points (ncps) by providing them with more budgetary resources , and calls for an increase in the number of information campaigns on patients’ rights to cross-border healthcare; emphasises the need to facilitate the process , through the revision of the cross-border healthcare directive , for patients who travel abroad for clinical trials and face issues such as a lack of clarity on follow-up protocols after their return home and on coverage of costs related to their clinical trial participation by national insurance agencies; calls on the commission and the member states to work together to conduct regular evaluations of the commission’s ehealth strategy from 2018 to ensure interconnected electronic health records for cancer patients at regional , national and european level; ### 42. deplores the fact that eu patients still face challenges in accessing healthcare services in other member states and that only a minority of patients are aware of their right to seek cross-border healthcare under the two existing frameworks: the cross-border healthcare directive 2011/24/eu and the social security regulation 883/2004; emphasises the need for better implementation of , and an improved financial model for the cross-border healthcare directive25 , notably to allow for mobility and access to highly specialised equipment and care through the reinforcement of the national contact points (ncps) by providing them with more budgetary resources , and the development of commission guidelines setting acceptable and harmonized review and approval timelines to expedite time-to-treatment in the eu under the social security regulation , and calls for an increase in the number of information campaigns on patients’ rights to cross-border healthcare as well as the development of a one-stop-shop for information on the eu’s cross-border access pathways; emphasises the need to facilitate the process through a holistic revision of the cross-border healthcare frameworks , giving equal consideration to the cross-border healthcare directive and the social security regulation , for patients who travel abroad for clinical trials and face issues such as a lack of clarity on follow-up protocols after their return home and on coverage of costs related to their clinical trial participation by national insurance agencies; calls on the commission and the member states to work together to conduct regular evaluations of the commission’s ehealth strategy from 2018 to ensure interconnected electronic health records for cancer patients at regional , national and european level;


### 43. calls for consideration of mutual recognition of medical qualifications in cancer care across the eu; ### 43. calls for consideration of mutual recognition of medical qualifications in cancer care across the eu , as requested in directive 2005/36/ec on the recognition of professional qualifications.1a


### 44. calls for full recognition of medical oncology as a specialist discipline , the establishment of pan-european quality standards for administering and supervising medical treatments for cancer , and the facilitation of patients’ access to cancer specialists so that they may benefit from innovations and access to early clinical trials on new promising drugs; ### 44. calls for full recognition of medical oncology as a specialist discipline , the establishment of pan-european quality standards for administering and supervising medical treatments for cancer , and the facilitation of patients’ access to cancer specialists so that they may benefit from innovations and access to early clinical trials on new promising drugs , surgery and radiotherapy;


### 45. calls for surgical skills in the eu to be strengthened via the recognition of surgical oncology as a specialist discipline , the establishment of pan-european quality standards for cancer surgery , the facilitation of patients’ access to ‘high-volume’ centres for cancer surgery and access to innovative surgical procedures; ### 45. calls for surgical skills in the eu to be strengthened via the recognition of surgical oncology as a specialist discipline , the establishment of pan-european quality standards for cancer surgery , the facilitation of patients’ access to ‘high-volume’ centres for cancer surgery or reference centres for complex treatments like cell and gene therapy and access to innovative surgical procedures;


### 46. supports the improvement of high-quality radiation therapy in the eu through the recognition of medical physics and radiation therapy as dedicated disciplines , the promotion of common education and training standards , and the greater investment of eu and national research and innovation funds in radiation therapy research; ### 46. supports the improvement of and stresses the importance of an increased and equal access to high-quality radiation diagnosis and therapy in the eu through a greater eu and national authorities investment in the adequate infrastructure , the recognition of medical physics and radiation therapy as dedicated disciplines , the promotion of common education and training standards , and the greater investment of eu and national research and innovation funds in radiation therapy research;


### 46. supports the improvement of high-quality radiation therapy in the eu through the recognition of medical physics and radiation therapy as dedicated disciplines , the promotion of common education and training standards , and the greater investment of eu and national research and innovation funds in radiation therapy research; ### 46. supports the improvement of , and an increased access to , high-quality radiation therapy in the eu through the recognition of medical physics and radiation therapy as dedicated disciplines , the promotion of common education and training standards , increased funding for member states to expand their radiation therapy infrastructure , and the greater investment of eu and national research and innovation funds in radiation therapy research;


### 47. welcomes the upcoming new action plan under the strategic agenda for medical ionising radiation applications (samira)26 which will support the security of supply of radioisotopes for cancer diagnosis and care and enhance the quality and safety of radiation technology in medicine; ### 47. welcomes the upcoming new action plan under the strategic agenda for medical ionising radiation applications (samira)26 highlighting the importance of nuclear medicine to tackle cancer. the actions included into the samira action plan should be implemented as quickly as possible , to facilitate innovation and supply of medical applications of radioisotopes and aiming at the good integration of radioisotopes in the medical practice. the plan should address regulatory gaps faced by the nuclear medicine sector and support: the inclusion of innovative nuclear medicine treatments into national cancer plans , the development of national level capacities for the effective delivery of nuclear medicine and the pan european implementation of common curricula for nuclear medicine which will support the security of supply of radioisotopes for cancer diagnosis and enhance the quality and safety of radiation technology in medicine in europe; calls on the commission to stimulate the implementation of existing technologies , notably reactors and particles accelerators , through existing financial instruments.


### 47. welcomes the upcoming new action plan under the strategic agenda for medical ionising radiation applications (samira)26 which will support the security of supply of radioisotopes for cancer diagnosis and care and enhance the quality and safety of radiation technology in medicine; ### 47. welcomes the upcoming new action plan under the strategic agenda for medical ionising radiation applications (samira)26 which will support the security of supply of radioisotopes for cancer diagnosis and care and enhance the quality and safety of radiation technology in medicine in europe; calls on the commission to stimulate the implementation of existing technologies , notably reactors and particles accelerators , through existing financial instruments;


### 47. welcomes the upcoming new action plan under the strategic agenda for medical ionising radiation applications (samira)26 which will support the security of supply of radioisotopes for cancer diagnosis and care and enhance the quality and safety of radiation technology in medicine; ### 47. welcomes the upcoming new action plan under the strategic agenda for medical ionising radiation applications (samira)26 which will support the security of supply of radioisotopes for cancer diagnosis and care and enhance the quality and safety of radiation technology in medicine; recalls that nuclear research reactors are needed for the production of medical isotopes and the eu needs to support the replacement of the current ageing fleet of reactors which have reached the end of their technical life-span and therefore calls on the commission to stimulate the implementation of existing technologies , notably reactors and particles accelerators , through existing financial instruments;


### 47. welcomes the upcoming new action plan under the strategic agenda for medical ionising radiation applications (samira)26 which will support the security of supply of radioisotopes for cancer diagnosis and care and enhance the quality and safety of radiation technology in medicine; ### 47. welcomes the upcoming new action plan under the strategic agenda for medical ionising radiation applications (samira)26 which will support the security of supply of radioisotopes for cancer diagnosis and treatment and enhance the quality and safety of radiation technology in medicine;


### 47. welcomes the upcoming new action plan under the strategic agenda for medical ionising radiation applications (samira)26 which will support the security of supply of radioisotopes for cancer diagnosis and care and enhance the quality and safety of radiation technology in medicine; ### 47. welcomes the new action plan under the strategic agenda for medical ionising radiation applications (samira)26 which will support the security of supply of radioisotopes for cancer diagnosis and care and enhance the quality and safety of radiation technology in medicine;


### 48. calls on the commission to promote , and on member states to strengthen , the role of general practitioners , paediatricians and primary care professionals , given their importance in patient referral to diagnostic tests and oncology specialists , as well as during cancer treatment and follow-up care; calls for the development of multidisciplinary decision-making in the framework of dedicated concertation meetings bringing together various cancer specialists; ### 48. calls on the commission to promote , and on member states to strengthen , the role of general practitioners , paediatricians and primary care professionals and specialist physicians , given their importance in patient referral to diagnostic tests and oncology specialists , as well as during cancer treatment and follow-up care; calls for the development of multidisciplinary decision-making in the framework of dedicated concertation meetings bringing together various cancer specialists; notes that such multidisciplinary care is of particular relevance in the context of lung cancer care as the disease has a complicated nature and requires a unique level of care coordination within a limited time; considers that respiratory physicians should thus have a leading role in the lung cancer multidisciplinary teams;


### 48. calls on the commission to promote , and on member states to strengthen , the role of general practitioners , paediatricians and primary care professionals , given their importance in patient referral to diagnostic tests and oncology specialists , as well as during cancer treatment and follow-up care; calls for the development of multidisciplinary decision-making in the framework of dedicated concertation meetings bringing together various cancer specialists; ### 48. calls on the commission to promote , and on member states to strengthen , the role of general practitioners , paediatricians and primary care professionals , given their importance in cancer prevention , early detection , patient referral to diagnostic tests and oncology specialists , as well as during cancer treatment and follow-up care; calls for the development of multidisciplinary decision-making in the framework of dedicated concertation meetings bringing together various cancer specialists; calls for the development of a personalized medicine approach guiding patients in tailor-made innovative and integrative oncology treatment strategies;


### 48. calls on the commission to promote , and on member states to strengthen , the role of general practitioners , paediatricians and primary care professionals , given their importance in patient referral to diagnostic tests and oncology specialists , as well as during cancer treatment and follow-up care; calls for the development of multidisciplinary decision-making in the framework of dedicated concertation meetings bringing together various cancer specialists; ### 48. calls on the commission to promote , and on member states to strengthen , the role of general practitioners , paediatricians and primary care professionals , given their importance in patient referral to diagnostic tests and oncology specialists , as well as during cancer treatment and follow-up care , and the role of psychologists and rehabilitation specialists; calls for the development of multidisciplinary decision-making in the framework of dedicated concertation meetings bringing together various cancer specialists; calls for the role of treatment coordinator to be made more widespread in order to ensure that patients receive appropriate coordination of specialist care and advice on how to use the health system;


### 48. calls on the commission to promote , and on member states to strengthen , the role of general practitioners , paediatricians and primary care professionals , given their importance in patient referral to diagnostic tests and oncology specialists , as well as during cancer treatment and follow-up care; calls for the development of multidisciplinary decision-making in the framework of dedicated concertation meetings bringing together various cancer specialists; ### 48. calls on the commission to promote , and on member states to strengthen , the role of general practitioners , paediatricians and primary care professionals and specialist physicians , given their importance in patient referral to diagnostic tests and oncology specialists , as well as during cancer treatment and follow-up care; calls for the development of multidisciplinary teams and decision-making in the framework of dedicated concertation meetings bringing together various cancer specialists


### 49. considers that the eu regulatory framework for the recognition of professional qualifications should be broadened to allow for the standardisation of cancer nursing education; ### 49. considers that the eu regulatory framework for the recognition of professional qualifications should be broadened to allow for the standardisation of cancer nursing education and education for other medical staff supporting the treatment process;;


### 51. encourages , where possible and safe , the use of ambulatory cancer treatments in order to preserve the quality of life of patients; calls on member states to implement or improve e-health technologies and telemedicine services to ensure the continuity of cancer care; ### 51. encourages , where possible and safe , the use of ambulatory cancer treatments in order to preserve the quality of life of patients; calls on member states to implement or improve e-health technologies and telemedicine services to ensure the continuity of cancer care; urges the deployment of horizon europe research funding to support the use of telemedicine , and to assist the establishment of evidence-based guidelines; calls for actions to ensure equal access to telemedicine services across the member states and for eu4health and digital europe funding support to increase digital literacy for patients and healthcare professionals;


### 51. encourages , where possible and safe , the use of ambulatory cancer treatments in order to preserve the quality of life of patients; calls on member states to implement or improve e-health technologies and telemedicine services to ensure the continuity of cancer care; ### 51. encourages , where possible and safe , the use of ambulatory one-day cancer treatments in order to preserve the quality of life of patients; calls on member states to implement or improve e-health technologies and telemedicine services to ensure the continuity of cancer care;


### 52. calls on the member states to provide optimal relief for advanced-stage cancer patients at the end of their lives in order to ease their pain and discomfort while preserving their dignity; supports more intensive exchanges and the implementation of best practices on hospice and palliative care at eu level; encourages member states to assess the number of palliative units in each region and to ensure sustainable funding and sufficient and well-trained human resources; ### 52. calls on the member states to provide optimal relief for advanced-stage cancer patients at the end of their lives in order to ease their pain and discomfort while preserving their dignity and taking into account the advance care planning and the autonomy of the patient; supports more intensive exchanges and the implementation of best practices on hospice and palliative care at eu level; calls for the development of child-specific palliative care , especially in member states where those cares are not yet widely provided; encourages member states to assess the number of palliative units in each region and to ensure sustainable funding and sufficient and well-trained human resources; supports the deeper cooperation between the healthcare system and the social assistance system in all member states;


### 52. calls on the member states to provide optimal relief for advanced-stage cancer patients at the end of their lives in order to ease their pain and discomfort while preserving their dignity; supports more intensive exchanges and the implementation of best practices on hospice and palliative care at eu level; encourages member states to assess the number of palliative units in each region and to ensure sustainable funding and sufficient and well-trained human resources; ### 52. calls on the member states to provide optimal relief for advanced-stage cancer patients at the end of their lives in order to ease their pain and discomfort while preserving their dignity; supports more intensive exchanges and the implementation of best practices on hospice and palliative care at eu level; encourages member states to assess the number of palliative units , both inpatient and outpatient , in each region in order to appropriately adjust their number to the needs of patients , as well as to minimise waiting times and to ensure sustainable funding and sufficient and well-trained human resources; supports and encourages deeper cooperation between the health and social welfare systems in all member states;


### 52. calls on the member states to provide optimal relief for advanced-stage cancer patients at the end of their lives in order to ease their pain and discomfort while preserving their dignity; supports more intensive exchanges and the implementation of best practices on hospice and palliative care at eu level; encourages member states to assess the number of palliative units in each region and to ensure sustainable funding and sufficient and well-trained human resources; ### 52. calls on the member states to provide optimal , integrated and multidisciplinary relief for advanced-stage cancer patients at the end of their lives in order to ease their pain and discomfort while preserving their dignity; supports more intensive exchanges and the implementation of best practices on hospice and home palliative care at eu level; encourages member states to assess the number of palliative units in each region and to ensure sustainable funding and sufficient and well-trained human resources;


### 53. encourages the commission and the member states to adopt specific quality assurance criteria (including adequate organisations , infrastructures and competences , multidisciplinary practice , continuing education for professionals , patient education and participation in clinical research) for accreditation standards to be applied to public and private hospitals treating cancer patients , in order to ensure the efficient , safe and equal management of cancers all over the eu; ### 53. encourages the commission and the member states to adopt specific quality assurance criteria (including adequate organisations , infrastructures and competences , multidisciplinary practice , continuing education for professionals , patient education and participation in clinical research , and joint clinical guidelines) for accreditation standards to be applied to public and private hospitals treating cancer patients , in order to ensure the efficient , safe and equal management of cancers all over the eu;


### 54. welcomes the planned establishment , as announced in europe’s beating cancer plan , of an eu network linking recognised national comprehensive cancer centres (reference centres) in every member state to facilitate the uptake of quality-assured diagnosis and treatments , including training , research and promotion of clinical trials across the eu; calls on the commission to identify such existing centres within the eu , to promote the establishment of at least one comprehensive cancer centre in each member state and to support the coordination of the network of these centres via a european cancer institute; ### 54. welcomes the planned establishment , as announced in europe’s beating cancer plan , of an eu network linking recognised national comprehensive cancer centres (reference centres) in every member state to facilitate the uptake of quality-assured diagnosis and treatments , including training , research and promotion of clinical trials across the eu; calls on the member states and the commission to support the establishment of such reference centres for rare cancers and cancers with complex treatments; calls on the commission to identify such existing centres within the eu , to promote the establishment of at least one comprehensive cancer centre in each member state and to support the coordination of the network of these centres via a european cancer institute; recommends the establishment of core objectives for the new network of centres as an early task; stresses that these objectives should include the reduction of inequalities , strengthening of translational , clinical and outcomes research , and integration of clinical care and research; notes that , when developing this eu network , the commission should consider the need to invest in state-of-the-art equipment and well-trained physicians and other healthcare specialists in various specialties , including nuclear medicine;


### 54. welcomes the planned establishment , as announced in europe’s beating cancer plan , of an eu network linking recognised national comprehensive cancer centres (reference centres) in every member state to facilitate the uptake of quality-assured diagnosis and treatments , including training , research and promotion of clinical trials across the eu; calls on the commission to identify such existing centres within the eu , to promote the establishment of at least one comprehensive cancer centre in each member state and to support the coordination of the network of these centres via a european cancer institute; ### 54. welcomes the planned establishment , as announced in europe’s beating cancer plan , of an eu network linking recognised national comprehensive cancer centres (reference centres) in every member state to facilitate the uptake of quality-assured diagnosis and treatments , including training , research and promotion of clinical trials across the eu , and to support the already existing european reference networks (erns) as well as the development of guidelines and quality assurance schemes for cancer types (e.g. blood cancers) that will not be covered by the knowledge center for cancer; calls on the commission to identify such existing centres within the eu , to promote the establishment of at least one comprehensive cancer centre in each member state and to support the coordination of the network of these centres via a european cancer institute;


### 54. welcomes the planned establishment , as announced in europe’s beating cancer plan , of an eu network linking recognised national comprehensive cancer centres (reference centres) in every member state to facilitate the uptake of quality-assured diagnosis and treatments , including training , research and promotion of clinical trials across the eu; calls on the commission to identify such existing centres within the eu , to promote the establishment of at least one comprehensive cancer centre in each member state and to support the coordination of the network of these centres via a european cancer institute; ### 54. welcomes the planned establishment , as announced in europe’s beating cancer plan , of an eu network linking recognised national comprehensive cancer centres (reference centres) in every member state to facilitate the uptake of quality-assured diagnosis and treatments , including training , research and promotion of clinical trials across the eu; calls on the commission to identify such existing centres within the eu , to promote the establishment of at least one comprehensive cancer centre in each member state and to support the coordination of the network of these centres via a european cancer institute; calls on the commission and the members states to support the sustainability of pre-existing cross-border collaborations , such as in the paediatric cancer sector , and the european reference networks;


### 54. welcomes the planned establishment , as announced in europe’s beating cancer plan , of an eu network linking recognised national comprehensive cancer centres (reference centres) in every member state to facilitate the uptake of quality-assured diagnosis and treatments , including training , research and promotion of clinical trials across the eu; calls on the commission to identify such existing centres within the eu , to promote the establishment of at least one comprehensive cancer centre in each member state and to support the coordination of the network of these centres via a european cancer institute; ### 54. welcomes the planned establishment , as announced in europe’s beating cancer plan , of an eu network linking recognised national comprehensive cancer centres (reference centres) in every member state to facilitate the uptake of quality-assured diagnosis and treatments , including training , research and promotion of clinical trials across the eu; calls on the member states and the commission to support the establishment of such reference centres for rare cancers and cancers with complex treatments; calls on the commission to identify such existing centres within the eu , to promote the establishment of at least one comprehensive cancer centre in each member state and to support the coordination of the network of these centres via a european cancer institute;


### 54. welcomes the planned establishment , as announced in europe’s beating cancer plan , of an eu network linking recognised national comprehensive cancer centres (reference centres) in every member state to facilitate the uptake of quality-assured diagnosis and treatments , including training , research and promotion of clinical trials across the eu; calls on the commission to identify such existing centres within the eu , to promote the establishment of at least one comprehensive cancer centre in each member state and to support the coordination of the network of these centres via a european cancer institute; ### 54. welcomes the planned establishment , as announced in europe’s beating cancer plan , of an eu network linking recognised national comprehensive cancer centres (reference centres) in every member state to facilitate the uptake of quality-assured diagnosis and treatments , including training , research and promotion of clinical trials across the eu , as well as the development of common standards of care; calls on the commission to identify such existing centres within the eu , to promote the establishment of at least one comprehensive cancer centre in each member state and to support the coordination of the network of these centres via a european cancer institute;


### 55. calls for the identification , reinforcement or creation in each member state of a national cancer control programme (nccp) , consisting of a unique structure , possibly a national cancer institute , in charge of the implementation and follow-up of the respective nccps , with adequate objectives and resources; recommends that the nccps are set up in coherence with the european guide for quality national cancer control programmes initiated by the european partnership for action against cancer (epaac); welcomes the setting up of a network of these organisations coordinated by the european cancer institute; ### 55. calls for the identification , reinforcement or creation in each member state of a national cancer control programme (nccp) , consisting of a unique structure , possibly a national cancer institute , in charge of the implementation and follow-up of the respective nccps , with adequate objectives and resources; recommends that the nccps are set up in coherence with the european guide for quality national cancer control programmes initiated by the european partnership for action against cancer (epaac); welcomes the setting up of a network of these organisations coordinated by the european cancer institute; calls for the inclusion of a dedicated paediatric cancer component in all nccps to ensure that appropriate resources and implementation programmes are allocated to the specific needs of these patients;


### 55. calls for the identification , reinforcement or creation in each member state of a national cancer control programme (nccp) , consisting of a unique structure , possibly a national cancer institute , in charge of the implementation and follow-up of the respective nccps , with adequate objectives and resources; recommends that the nccps are set up in coherence with the european guide for quality national cancer control programmes initiated by the european partnership for action against cancer (epaac); welcomes the setting up of a network of these organisations coordinated by the european cancer institute; ### 55. calls for the identification , reinforcement or creation in each member state of a national cancer control programme (nccp) , in coherence with who guidance on nccps , consisting of a unique structure , possibly a national cancer institute , in charge of the implementation and follow-up of the respective nccps , with adequate objectives and resources; recommends that the nccps are set up in coherence with the european guide for quality national cancer control programmes initiated by the european partnership for action against cancer (epaac); welcomes the setting up of a network of these organisations coordinated by the european cancer institute;


### iii.b equal access to cancer care: towards a european medicines market ### iii.b equal access to cancer care and treatment in all member states: towards a european medicines market


### 56. calls on the commission to strengthen the european medicines market in order to guarantee equal access to treatment , reduce medicine shortages , overcome the problem of high prices for innovative treatments , and improve cancer treatments for adults and children; ### 56. calls on the commission to strengthen the european medicines market in order to improve equal access to treatment , reduce medicine shortages , overcome the problem of high prices for innovative treatments , and improve cancer treatments for adults and children; encourages a multi-stakeholder dialogue on access to medicines and innovation based on models such as accelerate in the paediatric cancer sector and involving all relevant actors including academia , industry and patient representatives;


### 56. calls on the commission to strengthen the european medicines market in order to guarantee equal access to treatment , reduce medicine shortages , overcome the problem of high prices for innovative treatments , and improve cancer treatments for adults and children; ### 56. calls on the commission to strengthen the european medicines market in order to guarantee equal access to treatment , reduce medicine shortages , overcome the problem of high prices for innovative treatments , and improve cancer treatments for adults and children; encourages a multi-stakeholder dialogue on access to medicines and innovation based on models such as accelerate in the paediatric cancer sector and involving all relevant actors including academia , industry and patient representatives; considers , in this respect , that market access for nuclear medicine applications should be harmonised across all member states;


### 56. calls on the commission to strengthen the european medicines market in order to guarantee equal access to treatment , reduce medicine shortages , overcome the problem of high prices for innovative treatments , and improve cancer treatments for adults and children; ### 56. calls on the commission to strengthen the european medicines market in order to guarantee equal access to treatment , reduce medicine shortages , overcome the problem of high prices for innovative treatments , and improve cancer treatments for adults and children; encourages a multi-stakeholder dialogue on access to medicines and innovation based on models such as accelerate in the paediatric cancer sector and involving all relevant actors including academia , industry and patient representatives;


### 56. calls on the commission to strengthen the european medicines market in order to guarantee equal access to treatment , reduce medicine shortages , overcome the problem of high prices for innovative treatments , and improve cancer treatments for adults and children; ### 56. calls on the commission to strengthen the european medicines market in order to guarantee equal access to innovative treatment , including personalised medicine , reduce medicine shortages , overcome the problem of high prices for innovative treatments , and improve cancer treatments for adults and children;


### 58. notes that cancer patients are frequently affected by medicine shortages; calls on the commission to present a specific strategy for managing shortages of all medicines and medical products in europe and of cancer medicines in particular; supports the development of a common basket of the cancer drugs of which there may be shortages to ensure that patients have continuous access to appropriate treatment; ### 58. notes that cancer patients are frequently affected by medicine shortages and that severe disruptions in the supply of cancer treatments are highly detrimental for cancer patients , carers and families; calls on the commission to develop a clear and harmonised definition as well as detailed and transparent requirements and to present a specific strategy for managing shortages of all medicines and medical products in europe and of cancer medicines in particular; supports the development of a common basket of the cancer drugs of which there may be shortages to ensure that patients have continuous access to appropriate treatment;


### 58. notes that cancer patients are frequently affected by medicine shortages; calls on the commission to present a specific strategy for managing shortages of all medicines and medical products in europe and of cancer medicines in particular; supports the development of a common basket of the cancer drugs of which there may be shortages to ensure that patients have continuous access to appropriate treatment; ### 58. notes that cancer patients are frequently affected by medicine shortages; calls on the commission to develop a consistent definition of shortages and standardised reporting requirements as well as to present a specific strategy for managing shortages of all medicines and medical products in europe and of cancer medicines in particular; supports the development of a common basket of the cancer drugs of which there may be shortages to ensure that patients have continuous access to appropriate treatment , based on transparently and appropriately defined patient needs;


### 59. calls for the reinforcement and diversification of the supply chain , in particular that of cancer drugs , within the eu , close monitoring of medicine tensions and shortages , and the creation of a strategic stockpile of such medicines; ### 59. calls for the reinforcement and diversification of the supply chain , in particular that of cancer drugs , within the eu , close monitoring of medicine tensions and shortages at eu level , and the creation of a strategic stockpile of such medicines; urges the commission , in the context of the eu public procurement directive 2014/24/eu , to develop guidelines to support public procurement practices in the pharmaceutical field for cancer drugs , in particular with regard to the implementation of the criteria of the most economically advantageous tender (meat) , aimed at ensuring long-term sustainability , competition and security of supply and stimulating investment in manufacturing; calls for remedies against single-winner , price-only tenders that can cause severe price erosion , reducing the number of suppliers on the market and often resulting in short lead times and penalties being applied to companies , which in turn increases the risk of shortages of medical products; calls , in this respect , for the necessary measures to develop a robust supply chain for nuclear medicine which goes beyond irradiation and includes the supply of target material and processing capabilities;


### 59. calls for the reinforcement and diversification of the supply chain , in particular that of cancer drugs , within the eu , close monitoring of medicine tensions and shortages , and the creation of a strategic stockpile of such medicines; ### 59. calls for the reinforcement and diversification of the supply chain , in particular that of cancer drugs , within the eu , close monitoring of medicine tensions and shortages at eu level , and the creation of a strategic stockpile of such medicines; urges the commission , in the context of the eu public procurement directive 2014/24/eu , to develop guidelines to support public procurement practices in the pharmaceutical field for cancer drugs , in particular with regard to the implementation of the criteria of the most economically advantageous tender (meat) , aimed at ensuring long-term sustainability , competition and security of supply and stimulating investment in manufacturing;